The Role of Beta-Amyloid and Tau: CSF Protein Levels and PET Imaging

Course Information

Therapautic Area: Neurology
Format(s): Webcast
Credit(s): .50 AMA PRA Category 1 Credits™;.50 CNE contact hours
Activity Dates: December 7, 2017 to December 6, 2018


Program Overview

In this module of a Four-Part Expert Interview Series, Dr. Barry W. Rovner, along with Dr. Richard S. Isaacson, course chair, will provide learners with an update regarding beta-amyloid and tau biomarkers and their role in Alzheimer’s disease (AD) pathology and progression. Recent guidelines and trial data relating to beta-amyloid and tau will be reviewed, and clinical relevance debated. Drs. Rovner and Isaacson will also discuss the diagnostic criteria for Alzheimer’s disease and intervention techniques for the various stages of disease. Upon completion of this educational activity, learners will be better equipped with best practices for managing beta amyloid and tau levels in practice to provide optimal care for patients with AD.

Target Audience

Neurologists, internists, nurse practitioners, and other healthcare professionals involved in the management of patients with Alzheimer’s disease.

Learning Objectives

I. Discuss recent developments in the diagnosis of AD such as the role of beta-amyloid and tau biomarkers

II. Implement shared decision making with the patient and caregiver to develop individualized approach to diagnosis and treatment to improve the quality of life for patients with AD


Isaacson Head ShotRichard S. Isaacson, MD
Associate Professor of Neurology
Director, Alzheimer’s Prevention Clinic
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York



Rovner Head ShotBarry W. Rovner, MD
Professor, Departments of Neurology, Psychiatry, and Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Jefferson Hospital for Neuroscience
Philadelphia, Pennsylvania


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Faculty Relationship Identified With:
Richard S. Isaacson, MD Consultant/Advisor: Eli Lilly and Company; Neurotrack; 23 and Me
Barry W. Rovner, MD Nothing to disclose.

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski, Chelsey Benedek and Kim Cheramie, MSN, RN-BC hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of .50 CNE contact hours.

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 66% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact


Provided by AcademicCME-web